Anti-CD55, Recombinant [BU14]
Invented at University Of Birmingham
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 153263 |
| Applications | FACS IP |
| Antigen/Gene or Protein Targets | CD55 (CD97 ligand) |
| Synonyms | CD55 Molecule (Cromer Blood Group); CD55 Molecule; Decay Accelerating Factor For Complement (Cromer Blood Group); CD55 Antigen; DAF; CR; Decay Accelerating Factor For Complement; CROM; TC |
| Reactivity | Human |
| Relevance | CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumour aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours. |
| Host | Mouse |
| Subclass | IgG1 |
| Formulation | PBS |
| Concentration | 1mgml-1 |
| Research Area | Immunology |
| Notes |
Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma. Five products based on this clone: - Anti-CD55 [BU14], Mouse IgG1, Kappa - Anti-CD55 [BU14], Rabbit IgG, Kappa - Anti-CD55 [BU14], Human IgG4-S228P, Kappa - Anti-CD55 [BU14], Human IgG1, Kappa - Anti-CD55 [BU14], Human IgG1, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors |
References: 1 entry
Original hybridoma first published in: Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663.
Add a reference
References: 1 entry
Original hybridoma first published in: Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663.
Add a reference
